NURECA

Nureca Share Price

 

 

Start SIP in NURECA

Start SIP

Performance

  • Low
  • ₹271
  • High
  • ₹284
  • 52 Week Low
  • ₹204
  • 52 Week High
  • ₹343
  • Open Price₹284
  • Previous Close₹281
  • Volume10,766
  • 50 DMA₹285.36
  • 100 DMA₹279.04
  • 200 DMA₹274.62

Investment Returns

  • Over 1 Month -6.51%
  • Over 3 Month -2.72%
  • Over 6 Month + 17.47%
  • Over 1 Year -1.95%

Smart Investing Starts Here Start SIP with Nureca for Steady Growth!

Invest Now

Nureca Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 26
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 277
  • P/B Ratio
  • 1.4
  • Average True Range
  • 14.2
  • EPS
  • 11.15
  • Dividend Yield
  • 0
  • MACD Signal
  • -2.63
  • RSI
  • 43.76
  • MFI
  • 15.29

Nureca Financials

Nureca Technicals

EMA & SMA

Current Price
₹277.00
-4.15 (-1.48%)
pointer
  • Bearish Moving Average 12
  • Bullish Moving Average 4
  • 20 Day
  • ₹284.91
  • 50 Day
  • ₹285.36
  • 100 Day
  • ₹279.04
  • 200 Day
  • ₹274.62

Resistance and Support

277.45 Pivot Speed
  • R3 297.25
  • R2 290.80
  • R1 283.90
  • S1 270.55
  • S2 264.10
  • S3 257.20

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Nureca has an operating revenue of Rs. 143.30 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, Pre-tax margin of 1% needs improvement, ROE of 0% is poor and needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 5% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 18% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 66 which is a FAIR score but needs to improve its earnings, a RS Rating of 79 which is FAIR indicating the recent price performance, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 126 indicates it belongs to a poor industry group of Medical-Products and a Master Score of B is close to being the best. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Nureca Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-17 Quarterly Results & Others To consider other business matters. per share(20%)Final Dividend
2025-11-28 Buy Back of Shares
2025-11-10 Buy Back of Shares
2025-10-16 Quarterly Results & Others To consider other business matters. per share(20%)Final Dividend
2025-07-15 Quarterly Results
Date Purpose Remarks
2022-02-25 INTERIM Rs.3.00 per share(30%)Interim Dividend
View Nureca Dividend History Arrow

Nureca F&O

Nureca Shareholding Pattern

68.09%
0%
0%
0.09%
0%
29.73%
2.09%

About Nureca

  • NSE Symbol
  • NURECA
  • BSE Symbol
  • 543264
  • Chairman & Managing Director
  • Mr. Saurabh Goyal
  • ISIN
  • INE0DSF01015

Similar Stocks to Nureca

Nureca FAQs

Nureca share price is ₹277 As on 08 February, 2026 | 09:38

The Market Cap of Nureca is ₹277 Cr As on 08 February, 2026 | 09:38

The P/E ratio of Nureca is 26 As on 08 February, 2026 | 09:38

The PB ratio of Nureca is 1.4 As on 08 February, 2026 | 09:38

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23